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PURPOSE. To investigate whether we can identify different patterns of inflammation in the
aqueous humor of a uveal melanoma (UM)-containing eye, and whether these are related to
prognosis.
METHODS. Ninety samples of aqueous humor from UM-containing eyes were analyzed using a
high-throughput multiplex immunoassay that enables simultaneous analysis of 92 predefined
protein biomarkers. Cytokine expression was compared to clinical and histopathological
characteristics. Cluster analysis was performed, after which the clusters were compared with
clinical and histopathological tumor characteristics.
RESULTS. Cluster analysis revealed three distinct clusters, with one cluster showing hardly any
inflammatory cytokines, one showing intermediate levels, and one showing a high expression
of inflammation-related biomarkers. Significant differences between the clusters were seen
with regard to patient age (P ¼ 0.008), tumor prominence (P ¼ 0.001), ciliary body
involvement (P < 0.001), American Joint Committee on Cancer (AJCC) stage (P < 0.001),
monosomy of chromosome 3 (P ¼ 0.03), and gain of chromosome 8q (P ¼ 0.04), with the
cluster with a highest cytokine expression having the worst prognostic markers. Especially
apoptosis-related cytokines were differentially expressed.
CONCLUSIONS. Analysis of cytokines in the aqueous humor shows distinct differences between
aqueous humor samples and allocates these samples into three different prognostic tumor
clusters. Especially large tumors with ciliary body involvement and monosomy 3 were
associated with many cytokines, especially apoptosis-related cytokines. The presence of these
cytokines in the aqueous humor may play a role in the lack of effective antitumor immune
responses.
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Uveal melanoma (UM) is the most common primaryintraocular malignancy in adults, and may develop in the
choroid, ciliary body, or iris. While UM accounts for 5% of all
malignant melanoma, it accounts for 13% of deaths due to a
malignant melanoma.1 Standard treatment options for the
primary tumor comprise radiotherapy (106ruthenium or 125io-
dine brachytherapy, proton beam therapy, or stereotactic
radiation) or surgery (resection or enucleation).2,3 No systemic
therapy has yet been demonstrated to improve survival in the
metastatic setting, but this malignancy is potentially an ideal
candidate for adjuvant therapy, as several markers are able to
accurately predict which patients will develop metastases.
Useful parameters include specific chromosome aberrations,4
mRNA expression patterns,5 and mutations, such as those in
the BRCA1-associated protein 1 (BAP1) gene.6 Immunohisto-
chemical staining for BAP1 protein can also be used for
prognostication.7–9 Loss of chromosome 3, loss of nuclear BAP1
expression, and a class 2 gene expression profile usually occur
together.7,10,11
Loss of chromosome 3/BAP1 expression is associated with
an increased number of lymphocytes and macrophages in
primary UM.12,13 However, the presence of an inflammatory
phenotype is linked to a bad and not a good prognosis.
Several studies have shown that a range of different proteins,
including cytokines, can be identified in anterior chamber fluid
and vitreous.8,9,14–17 The vitreous fluid of UM-containing eyes
showed high concentrations of several inflammatory cytokines
and chemokines that correlated predominantly with tumor size,
and with the presence of an immune cell infiltrate.18 These
studies did not look at the chromosome status.
Usui et al.14 compared immune mediators in aqueous humor
samples between eyes with a UM and with benign intraocular
tumors.14 Aqueous humor levels of angiogenin, IL-8 (CXCL8),
and monocyte chemoattractant protein (MCP)-1 (CCL2) were
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significantly higher in eyes with UM compared to the fluid
from eyes with different types of benign tumors (P < 0.05). Ly
et al.19 observed that aqueous humor samples of UM eyes often
showed increased levels of a range of inflammation-related
cytokines, when compared to cataract eyes. Increased IL-6 and
macrophage migration inhibitory factor (MIF) expression were
found to correlate with ciliary body involvement and the
presence of an epithelioid cell type, while a high RANTES and
vascular endothelial growth factor (VEGF) expression correlat-
ed with a large largest basal diameter (LBD) and tumor height.
However, none of the cytokine levels were of predictive value
for survival.
In order to determine the tumor’s chromosome or mRNA
status or BAP1 expression for prognostication, one needs to
have tumor material, obtained either after enucleation or
resection or by taking a biopsy. Success rates of the genetic
typing of the tumor vary between 78% and 93%, depending on
the surgical technique and tumor location.20–22 Disadvantages
include the need for using an operating room, technical
challenges in smaller tumors, and a small but present risk of
surgical complications. A liquid biopsy from the anterior
chamber is technically less challenging and can be performed
as an outpatient procedure, using topical anesthesia. As an
inflammatory phenotype is associated with the prognostic
parameters monosomy 3 and mRNA class 2,10 we hypothesized
that one can determine the prognostic category of a UM by
studying cytokines in the aqueous humor. Furthermore, an
analysis of aqueous humor might be used to determine
whether a tumor is likely to express immune checkpoint
inhibitors, potentially offering a selection method for choosing
patients for immunotherapy.23 Information obtained from a
liquid biopsy might therefore be used for prognostication,
selection for inclusion in adjuvant trials, or selection for
participation in intensified screening programs for early
detection of metastases. We set out to determine the presence
of a large selection of cytokines in the aqueous humor of UM-
containing eyes, obtained by enucleation, and compared their
presence with clinical and histological information.
MATERIALS AND METHODS
Study Approval
This project was approved by the Biobank of the LUMC
(number: Uveamelanoomlab-2019-4, approval May 2019). The
research adhered to Dutch law and the tenets of the
Declaration of Helsinki (World Medical Association of Decla-
ration 2013; ethical principles for medical research involving
human subjects).
Clinical Characteristics and Histopathological
Examination
This study was conducted at the Department of Ophthalmology,
Leiden University Medical Center (LUMC), Leiden, The Nether-
lands. We used 90 samples of aqueous humor that were obtained
from 90 patients who underwent enucleation for UM at the
LUMC between 1999 and 2016. Clinical data were obtained from
medical files and histopathological data from pathology reports
(Table 1). Anterior chamber paracentesis was performed
immediately after enucleation, by a researcher in the laboratory
of Ophthalmology, using a 23-gauge needle, and aqueous humor
was frozen at 808C and stored until the experiment was
performed. Following retrieval of aqueous humor, a tumor
sample was taken for storage for DNA or mRNA analysis, and the
remaining tumor tissue was formalin fixed (4% neutral buffered)
for 24 hours and subsequently embedded in paraffin.
Evaluation on hematoxylin- and eosin-stained 4-lm-thick
sections included largest basal diameter (LBD, in millimeters),
thickness (in millimeters), mitotic count (per 2 mm2 at 340
magnification, counting eight high-power fields), tumor
location, and cell type (assessed according to the Armed
Forces Institute of Pathology atlas24; a ‘‘mixed’’ cell type is
defined when spindle and epithelioid cells are both present as
at least 5% of tumor cells). Immunohistochemistry (IHC) of
BAP1 was performed as previously described, assessed by a
pathologist specialized in ophthalmic oncology.9 Tumors were
scored as BAP1 positive or negative according to the nuclear
staining, using a mouse monoclonal antibody raised against
amino acids 430 to 729 of human BAP1 (clone sc-28383, 1:50
dilution; Santa Cruz Biotechnology, Dallas, TX, USA). Tumors
were staged in accordance with the 8th edition of the
American Joint Committee on Cancer (AJCC) staging manual.25
Assessment of the clinical extent of retinal detachment (RD)
and the presence of subretinal fluid was evaluated and scored
by an experienced clinician using five commonly used
categories (from 0 [representing no RD] to 4 [representing
complete RD]).26,27
For follow-up, we used the period of time between the
enucleation date and the last date for which follow-up was
available. This information was obtained from the patient’s
charts and through the Dutch National Registry.28 The average
time of follow-up in the 84 cases was 58 months, and at the
end of follow-up, 34 patients were alive (with 18/34 patients
having a follow-up of at least 5 years and 16 patients of at least
2 years); 50 patients had passed away—37 died from
metastases of UM, and 13 of other causes.
Cytogenetic Analysis of Tumor Material
Genetic information was obtained from the Department of
Clinical Genetics at the LUMC, as described before.28
Protein Measurement
Proteins were measured in the aqueous humor using the Olink
Immuno-Oncology panel (Olink Proteomics AB, Uppsala,
Sweden) according to the manufacturer’s instructions. The
Proximity Extension Assay (PEA) technology has been de-
scribed,29 and enables measuring 92 proteins in 90 samples
and 6 controls, using 1 lL of each sample, as stated: ‘‘pairs of
oligonucleotide-labelled antibody probes bind to their targeted
protein, and if the two probes are brought in close proximity,
the oligonucleotides will hybridize in a pairwise manner. The
addition of a DNA polymerase leads to a proximity-dependent
DNA polymerization event, generating a unique PCR target
sequence. The resulting DNA sequence is subsequently
detected and quantified using a microfluidic real-time PCR
instrument (Biomark HD, Fluidigm). The final assay read-out is
presented in Normalized Protein eXpression (NPX) values,
which is an arbitrary unit on a log2-scale where an increased
value corresponds to a higher protein expression.’’ All assay
validation data (detection limits, intra- and interassay precision
data, and so on) are available on the manufacturer’s website
(www.olink.com; in the public domain). This includes the
measuring ranges defined by the lower limit of quantification
(LLOQ) and upper limit of qualification (ULOQ).
Data Selection Criteria
We determined the presence of 92 inflammation-related
cytokines in anterior chamber fluid of 90 enucleated UM-
containing eyes to test whether these cytokines can differen-
tiate between prognostically good and bad UM. A total of 88
samples (98%) passed the quality control test.30 One sample
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TABLE 1. Characteristics of UM Patients Primarily Enucleated in the LUMC Between 1999 and 2016 (n¼84), Divided Into Three Clusters, Based on
Cytokine Expression in the Aqueous Humor
Clinical and Histopathological Characteristics
Patients, n (%)*
Cluster 1,
n ¼ 37
Cluster 2,
n ¼ 36
Cluster 3,
n ¼ 11 P Value
Sex 0.56†
Females 18 (49) 14 (61) 6 (55)
Males 19 (51) 22 (39) 5 (46)
Eye 0.63†
OD 18 (49) 21 (58) 5 (45)
OS 19 (51) 15 (42) 6 (55)
Age at enucleation, mean, y (6SD) 55 (614) 62 (615) 70 (611) 0.008§
Eye color, known in 58 cases 0.007†
Light: blue, gray, green, hazel 16 (76) 26 (90) 3 (38)
Dark: brown 5 (24) 3 (10) 5 (63)
Largest basal tumor diameter in mm, mean (6SD) 12.2 (62.7) 12.9 (62.8) 14.7 (63.1) 0.04§
Tumor prominence in mm, mean (6SD) 6.4 (62.8) 8.2 (62.6) 9.6 (62.9) 0.001§
Ciliary body involvement
No 32 (87) 20 (56) 3 (27) <0.001†
Yes 5 (14) 16 (44) 8 (73)
Mitotic countj j mean (6SD) 4.4 (63.8) 5.1 (63.0) 7.6 (69.1) 0.16§
Histopathological cell type 0.048†
Spindle cell 17 (46) 10 (28) 1 (9)
Epithelioid or mixed cell type 20 (54) 26 (72) 10 (91)
Pigmentation of the tumor, known in 80 cases 0.57†
None to limited 20 (56) 20 (59) 4 (40)
Moderate to intense 16 (44) 14 (41) 6 (60)
Bruch’s membrane broken, known in 80 cases 0.21†
Unclear 6 (17) 4 (11) 3 (27)
Intact 10 (29) 4 (11) 2 (18)
Broken 18 (53) 27 (77) 6 (54)
Subretinal fluid 0.38‡
No subretinal fluid 1 1 2
Subretinal fluid: detachment over and around the melanoma 15 12 1
Subtle fluid at 6 o’clock and locally within the vascular arcade 13 11 5
Detachment of two to three quadrants 7 10 1
Total detachment 1 2 2
AJCC stage <0.001‡
I 6 (17) 1 (3) 0 (0)
IIA 16 (44) 10 (28) 0 (0)
IIB 9 (25) 11 (31) 2 (18)
IIIA, IIIB, IIIC 5 (14) 14 (39) 7 (64)
IV 0 (0) 0 (0) 2 (18)
Metastases
No 23 (62) 18 (50) 3 (27) 0.12†
Yes 14 (38) 18 (50) 8 (73)
Vital status 0.17†
Death due to UM metastases 12 (32) 18 (50) 7 (64)
Death due to other causes 6 (16) 7 (19) 0 (0)
Alive at last follow-up date 19 (51) 11 (31) 4 (36)
Monosomy 3 status, known in 81 cases 0.03†
No 16 (46) 14 (39) 1 (10)
Yes 19 (54) 22 (61) 9 (90)
8q status, known in 75 cases 0.04†
No gain of 8q 15 (42) 9 (26) 0 (0)
Gain of 8q 21 (58) 26 (74) 9 (100)
BAP1 staining, known in 71 cases 0.18†
Positive 16 (57) 12 (35) 3 (33)
Negative 12 (43) 22 (65) 6 (67)
* Percentages are rounded and may not total 100.
† Pearson v2 test.
‡ Linear-by-linear association.
§ 1-way ANOVA.
j j n mitosis per mm2 with340 magnification and 8 high-power fields.
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was removed due to being an exceptional outlier, and one
sample due to excessive variability (see Supplementary Fig.
S1). In total, samples from 84 eyes were included in the
analysis (for characteristics of the tumors see Table 1).
Eight of the 92 biomarkers (IFN-beta, IL2, IL5, IL13, IL-21,
CXCL12, IFN-gamma, and TNF) were always below the 5%
limit of detection (LOD) and were not studied further. Our
analysis therefore included information on 84 biomarkers (see
Supplementary Fig. S2).
Statistical Analysis
All clinical, histopathological, and cytogenetic data were
collected in an SPSS database. Analyses were subsequently
performed using both the statistical programming language R,
version 1.14.4 (R Foundation for Statistical Computing, Vienna,
Austria), including the packages for data science Tidyverse,
Broom, Grepel, and Gplots, and SPSS (IBM SPSS Statistics for
Windows, Version 23.0; IBM Corp., Armonk, NY, USA).
Population characteristics were described using medians
and percentages. The Pearson v2 test was used to analyze
categorical data, the Student’s t-test to compare means
between two groups, and analysis of variance (ANOVA) to
analyze the significance between the means of more than two
groups, for example, the different clusters, including a Tukey’s
honestly significant difference (HSD) post hoc test.
A volcano plot was made to show significant changes among
the biomarkers in relation to tumor characteristics. Kaplan-Meier
curves were made and the logrank test was used to analyze
significance. Differences were considered to be significant if P <
0.05 after correction for multiple testing, if indicated.
In order to perform a nonsupervised clustering using the 84
samples, the k-means clustering algorithm was used. All assays
were scaled using the mean centering with standard deviation
(Z-scores), before an unsupervised clustering algorithm was
applied. An elbow plot was used to determine the number of
underlying clusters (Supplementary Fig. S3). A scatterplot
depicting the frequency of positive cytokines among the
different AJCC stages was created using UnivarScatter function
in MATLAB and Statistics Toolbox Release 2018a (MathWorks,
Natick, MA, USA).
RESULTS
Cytokine Expression and Tumor Characteristics
We wondered whether one could take an aqueous humor
sample of a UM-containing eye to determine the patient’s
FIGURE 1. Cluster analysis of 84 aqueous humor samples from UM eyes. Heat map ordered by clustering of 84 aqueous humor samples from UM
eyes reveals three distinct clusters, 1 (n¼ 37), 2 (n¼ 36), and 3 (n¼ 11), which are linked to metastatic death due to UM. The heat map shows the
supervised clustering where the colors on the left represent the three different clusters: Cluster 1 is displayed in green, cluster 3 in red, and cluster
2 in blue.
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prognosis, and whether we could use the presence of
cytokines in the anterior chamber to identify specific
subgroups of patients. Levels of expression of 84 oncology-
and inflammation-related cytokines were determined in the
aqueous humor of 84 UM-containing eyes. A heat map of the
different samples shows the expression levels of the cytokines
in the different samples, indicating a high variability in the
number of cytokines present (Fig. 1).
We noticed a positive correlation between the number of
positive cytokines and the presence of epithelioid cells (Mann-
Whitney U test, P ¼ 0.006), histopathological involvement of
the ciliary body (Mann-Whitney U test, P < 0.001), AJCC stage
(Kruskal-Wallis test, P < 0.001, Fig. 2) and gain of chromosome
8q (Mann-Whitney U test, P ¼ 0.019). The association with
monosomy 3 did not reach statistical significance (Mann-
Whitney U test, P ¼ 0.095).
Cluster Analysis
We determined whether we could find clusters of cases with a
similar cytokine expression pattern. Unsupervised clustering
provided an optimum of three clusters (see Supplementary Fig.
S3). A principal component analysis was performed to visualize
the three clusters (Fig. 3). In cluster 1 (n ¼ 37), very few
cytokines were present in the aqueous humor; cluster 2 (n ¼
36) showed an intermediate number of expressed cytokines. In
contrast, cluster 3 (n ¼ 11) revealed expression of many
cytokines.
The most differentially expressed cytokines among the
three clusters were adenosine deaminase (ADA), CD244,
CD40, galactin-9 (Gal-9), MCP-3, programmed death-ligand 1
(PD-L1), tumor necrosis factor receptor superfamily 21
(TNFRSF21), and tumor necrosis factor-related apoptosis-
inducing ligand (TRAIL).
The three clusters differed significantly in patient age (P ¼
0.008), eye color (P¼ 0.007), LBD (P¼ 0.041), prominence (P
¼ 0.001), AJCC stage (P < 0.001), ciliary body involvement (P
< 0.001), cell type (P ¼ 0.048), monosomy of chromosome 3
(P ¼ 0.03), and amplification of chromosome 8q (P ¼ 0.04),
with the two clusters with more cytokines showing the worst
prognostic markers. Given the inflammatory component of
these data, we correlated the presence and extent of exudative
retinal detachment to the clusters; we did not find any
correlation to the clusters.
FIGURE 2. Frequency of cytokines with a positive expression (an
expression value above the median), displayed per AJCC stage
(Kruskal-Wallis test, P < 0.001).
FIGURE 3. Visualization of clusters aided by the principal component analysis. The graph illustrates how the three clusters detected with k-means
are separated, with principle component 1 (PC1) explaining 50%, PC2 explaining 6%, and PC3 explaining 4% of variation, indicating that individual
higher-order components explain little variance. Cluster 1 is displayed in green (n¼ 37), cluster 2 is displayed in blue (n¼ 36), and cluster 3 in red
(n¼ 11).
Aqueous Humor Biopsies in UM IOVS j November 2019 j Vol. 60 j No. 14 j 4744
Downloaded from iovs.arvojournals.org on 11/27/2019
Characteristics of Cluster 3
The 11 patients in cluster 3 with the highest number of
cytokines in the anterior chamber were significantly older at
enucleation, with a mean age of 70, in comparison with
clusters 1 and 2 (with a mean age of 55 and 62, respectively)
(Table 1, 1-way ANOVA, P ¼ 0.008). The patients in cluster 3
more often had dark eyes (63%) than patients in clusters 1 and
2 (24% and 10%, respectively) (Pearson v2 test, P ¼ 0.007).
The tumors of cluster 3 were significantly larger than
tumors in clusters 1 and 2 (mean LBD was 14.7 vs. 12.2 and
12.9 mm, respectively, P ¼ 0.04), more often showed an
epithelioid or mixed cell type, and more often showed
monosomy 3 (90% in cluster 3, vs. 51% and 64% in clusters 1
and 2, respectively, P¼ 0.03, Pearson v2 test). Additionally, all
tumors in cluster 3 showed gain of 8q, which was significantly
more than in cluster 1 or 2 (with 58% and 76%, respectively) (P
¼ 0.04, Pearson v2 test).
Survival Differences Between the Clusters
A Kaplan-Meijer survival curve of the three clusters showed a
significant difference in melanoma-related survival between
clusters 1 and 2 (logrank test, P¼ 0.02) and between clusters 1
and 3 (logrank test, P ¼ 0.004). There was no significant
difference in survival between clusters 2 and 3 (logrank test, P
¼ 0.14) (Fig. 4). In cluster 1, 12 out of 18 patient deaths were
due to metastatic UM; in cluster 2, 18 out of 25 patients died of
metastases, and in cluster 3, all seven deaths were caused by
metastatic disease from a UM.
Multivariate Analyses
When using the most significant associations in a multivariate
analysis (1-way MANOVA test with Tukey’s HSD post hoc
correction, details provided in Table 2), we observed that
involvement of the ciliary body was the most significant
parameter to differentiate between the clusters (with a
significance of P < 0.001 between clusters 1 and 3).
In a multivariate analysis, eye color remained statistically
significant as well: Cluster 3 contained more eyes with brown
irises than cluster 2 (P ¼ 0.017). Also, the mean age at
enucleation remained significantly different between clusters 1
and 3 (P ¼ 0.028). When looking at chromosomal abnormal-
ities, a gain of 8q remained significantly different between
clusters 1 and 3 (P ¼ 0.008).
Cytokines Involved in Apoptosis
Interestingly, out of the most differentially expressed cytokines
between the three clusters, four are involved in the process of
apoptosis (CD40, Gal-9, TNFRSF21, and TRAIL). TNFRSF9 was
the only cytokine that was linked to both chromosome 8q and
chromosome 3. This implies a potential role for apoptosis-
FIGURE 4. (A) Cluster 1 has a better survival than clusters 2 and 3. Survival in cluster 1 differs significantly from cluster 2 (logrank test, P¼0.02) and
cluster 3 (logrank test, P¼0.004). Survival in clusters 2 and 3 does not differ significantly (logrank test, P¼0.137). (B) Survival curves of monosomy
3 tumors versus disomy 3 tumors of all tumors involved in this study (P < 0.01). (C) Survival curves based on the BAP1 protein expression of all
tumors involved in this study (P < 0.01).
TABLE 2. Comparison of Clinical, Histopathological, and Chromosom-
al Characteristics Between the Three Clusters. Significant Results of
Multivariate Analysis With Tukey HSD Multiple-Comparison Correction
Characteristic
Clusters
Compared
Difference
of Mean Significance
Age at enucleation, mean† 0.032
1, 2 7.98 0.34
1, 3 17.57* 0.028
2, 3 9.59 0.14
Eye color† 0.014
1, 2 0.28 0.20
1, 3 0.12 0.79
2, 3 0.40* 0.017
Ciliary body involvement† <0.001
1, 2 0.38 0.09
1, 3 0.87* <0.001
2, 3 0.49* 0.006
Tumor prominence† 0.015
1, 2 0.74 0.70
1, 3 2.90* 0.027
2, 3 2.16* 0.028
Gain of 8q† 0.011
1, 2 0.37 0.058
1, 3 0.58* 0.008
2, 3 0.37 0.30
AJCC stage†: I/IIAB/IIIABC/IV <0.001
1, 2 0.68 0.058
1, 3 1.79* <0.001
2, 3 1.11* <0.001
Bold values indicate statistical significance P < 0.05.
* The mean difference is significant at the 0.05 level.
† 1-way MANOVA test with Tukey HSD correction.
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related cytokines in prognostically unfavorable UM. When
looking at the association between the presence of these
biomarkers and survival, we observed no significant difference
in survival between low and high levels of TRAIL (logrank, P¼
0.069).
However, we did find significant differences in survival
when looking at low versus high levels of CD40 (logrank, P¼
0.007), Gal-9 (logrank, P ¼ 0.011), TNFRSF9 (logrank, P ¼
0.014) and TNFRSF21 (logrank, P ¼ 0.005), and FASLG
(logrank, P ¼ 0.011) with high levels being expressed in the
aqueous humor of tumors with the worst survival.
DISCUSSION
To determine whether one can use a liquid biopsy in order to
discriminate between high- and low-risk UM, we analyzed the
presence and quantity of 84 proteins related to oncology or
immunology in aqueous humor samples of 84 UM-containing
eyes. A cluster analysis based on cytokine expression identified
three clusters, which revealed significant differences when
compared to clinical, histopathological, and chromosomal
characteristics. While most tumors in cluster 3 had monosomy
3 and all had a gain of 8q, we found that involvement of the
ciliary body was of more importance in differentiating between
the three clusters than chromosome status or tumor size. The
close association between the ciliary body and the anterior
chamber may provide an anatomic explanation. De Lange et
al.30 and Singh et al.31 demonstrated that 8q is an early
chromosomal change in the development of UM. Gezgin et
al.12 recently showed that tumors with disomy 3 and extra
copies of 8q already displayed an inflammatory phenotype.
The cluster analysis led to some new insights into tumor
biology. When comparing the cytokines between the groups, it
was noticed that many of the most differentially expressed
cytokines were related to apoptosis. TRAIL, also known as
Apo2L, is part of the TNF gene superfamily that has the
capacity to induce apoptosis. TRAIL has been recognized as a
therapeutic modality via TRAIL-induced apoptosis. When we
looked at the survival and compared cases with low and high
TRAIL levels in the aqueous humor, survival did not differ
significantly.
Another important inducer of apoptosis is FASLG: We found
that FASLG expression in the aqueous humor was related to
survival, with high levels corresponding to poor survival. A
prior study analyzed the TCGA database and found that high
mRNA levels of FASLG in the tumor were associated with a
significantly worse prognosis (P < 0.001).32 A study by Zhu et
al.32 suggested that FASLG expression is associated with T-cell
infiltrate.
Galactin-9 has been identified as a clinical predictor in
UM.33 Also, Gal-9 has been studied in tumor material and
plasma of patients with metastatic melanoma. It is thought that
Gal-9 promotes the alternatively activated macrophage M2
phenotype.34 When looking at levels of Gal-9 in the aqueous
humor in relation to survival, we found that high levels of Gal-9
were significantly related to a worse survival (logrank, P ¼
0.015). Also, Gal-9 in the aqueous humor significantly
corresponded to expression of the immune checkpoint
inhibitor PD-L1 in the aqueous humor (Spearman correlation,
n¼ 84, P < 0.001). This corresponds to the significant relation
between Gal-9 and PD-L1 expression in the tumor, as was
found using the TCGA database.33
While in our study high levels of Gal-9 correspond to a
worse survival, a study analyzing the TCGA UM cohort found
that patients with a lower expression of Gal-9 in the tumor
had worse survival rates.35 We hypothesize that high levels of
Gal-9 in the anterior chamber of prognostically bad UM is
plausible as expression of Gal-9 is stimulated in a proin-
flammatory environment,36 which is the case in UM with an
inflammatory phenotype.37,38 Galactin-9 has been proven to
impair the function of NK cells39 as well as leading to influx
of forkhead box P3 (FOXP3) positive regulatory T-cells, which
are independent predictors of worse survival in UM.36,38 All
these data indicate the presence of a wide range of molecules
in the anterior chamber that have immunosuppressive
qualities.
A strong point in this study is that the assay requires only 1
lL aqueous humor, an amount that can be obtained in an
outpatient setting. Studies in other ocular malignancies have
already demonstrated that aqueous humor can serve as a
surrogate tumor biopsy for analyses, such as the detection of
cell-free DNA for genetic analysis in retinoblastoma and the
measurement of IL-10 levels as a biomarker for intraocular
lymphoma.40–42
The ciliary body is specifically listed as a parameter in
differentiating prognostic categories in the Cancer Staging
Manual of the AJCC for staging ciliary body and choroidal
melanoma.43 A reason for the high expression of cytokines in
the anterior chamber fluid of cluster 3 tumors could be the
anatomic involvement of the ciliary body, which produces the
aqueous humor. Uveal melanomas with involvement of the
ciliary body are more aggressive tumors, and may cause more
cell turnover and cell death, leading to more leakage of
inflammatory mediators.
In conclusion, we observed a large variation in the presence
of a wide range of cytokines in the aqueous humor of UM-
containing eyes, leading to the identification of three clusters,
which differ with regard to patient age, AJCC category, ciliary
body involvement, and chromosome 8q amplification, sup-
porting the previous finding of an association between
chromosome 8q amplification and inflammation.12
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